Videos

Treatment of Multiple Myeloma with High-Risk Cytogenetics

Approach to Unresectable Stage 4 Gastric Adenocarcinoma

Karen Reckamp, MD, co-director of the Thoracic Oncology Program at the City of Hope Comprehensive Cancer Center, discusses combinations with immunotherapy in lung cancer at the International Lung Cancer Congress. She says this is a very hot topic in the field right now.

Sanjiv S. Agarwala, MD, chairman of medical oncology at St. Luke’s University Health Network, discusses the combination of immunotherapy and a histone deacetylase inhibitor in patients with melanoma, as well as other types of cancer.

Jacqueline D. Barrientos, MD, MS, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the most recent advances in mantle cell lymphoma, as well as the challenges investigators still face in the field.

Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses genotyping in lung cancer, particularly focusing on&nbsp;<em>ROS1&nbsp;</em>and&nbsp;<em>TRK&nbsp;</em>mutations.

Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.

Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.&nbsp;

Considering Triplet Therapy for Nondriver NSCLC